Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

81.60B

Market cap81.60B

Price-Earnings ratio

18.97

Price-Earnings ratio18.97

Dividend yield

0.45%

Dividend yield0.45%

Average volume

738.85K

Average volume738.85K

High today

$791.05

High today$791.05

Low today

$768.75

Low today$768.75

Open price

$781.08

Open price$781.08

Volume

621.13K

Volume621.13K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$476.49

52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $772.19, giving the company a market capitalization of 81.6B. It carries a P/E multiple of 18.97 and pays a dividend yield of 44.7%.

During the trading session on 2026-02-24, Regeneron(REGN) shares reached a daily high of $791.05 and a low of $768.75. At a current price of $772.19, the stock is +0.4% higher than the low and still -2.4% under the high.

Trading volume for Regeneron(REGN) stock has reached 621.13K, versus its average volume of 738.85K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

Simply Wall St 6h

Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals and Sanofi recently received U.S. FDA approval for Dupixent to treat allergic fungal rhinosinusitis (AFRS) in adults and children aged...

Benzinga 9h

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining? AFRS is a condition characterized by allergic hypersensitivity to fungi,...

TipRanks 13h

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult and pedi...

Analyst ratings

72%

of 29 ratings

Buy

72.4%

Hold

27.6%

Sell

More REGN News

Nasdaq 7d

Ex-Dividend Reminder: ONE Gas, AstraZeneca and Regeneron Pharmaceuticals

Looking at the universe of stocks we cover at Dividend Channel, on 2/20/26, ONE Gas, Inc. (Symbol: OGS), AstraZeneca plc (Symbol: AZN), and Regeneron Pharmaceut...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

MercadoLibre

Constellation Brands

abrdn Physical Precious M…

ServiceNow

Cipher Mining

Palo Alto Networks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.